Organon & Co. $OGN Stake Lessened by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its stake in Organon & Co. (NYSE:OGN) by 3.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,265,280 shares of the company’s stock after selling 118,860 shares during the period. Dimensional Fund Advisors LP’s holdings in Organon & Co. were worth $19,553,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in OGN. Farther Finance Advisors LLC grew its holdings in Organon & Co. by 87.8% during the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after acquiring an additional 2,033 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in shares of Organon & Co. in the 4th quarter worth about $44,000. Kestra Advisory Services LLC acquired a new stake in shares of Organon & Co. in the 4th quarter valued at about $47,000. Empowered Funds LLC acquired a new stake in shares of Organon & Co. in the 4th quarter valued at about $74,000. Finally, Oxford Asset Management LLP acquired a new stake in shares of Organon & Co. in the 4th quarter valued at about $74,000. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Price Performance

OGN opened at $13.55 on Friday. The firm has a market cap of $3.56 billion, a price-to-earnings ratio of 17.60, a price-to-earnings-growth ratio of 1.26 and a beta of 1.55. Organon & Co. has a fifty-two week low of $5.69 and a fifty-two week high of $13.60. The company’s 50-day moving average price is $13.49 and its 200 day moving average price is $10.56. The company has a quick ratio of 1.42, a current ratio of 1.95 and a debt-to-equity ratio of 8.43.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.’s payout ratio is presently 10.39%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $5.00 to $14.00 in a report on Tuesday, April 28th. BNP Paribas Exane restated a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Finally, Weiss Ratings downgraded Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday. Five research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.